Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia Resuming study following suspension of enrollment due to escalation of COVID-19 pandemic Data readout expected in 1H 2022 Also on track to recommence separate Phase 2...
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
TigerConnect Closes $45M Series D To Meet Soaring DemandCare Team Collaboration Platform Revenue Grew 30% Since COVID-19 Onset, Added 1,000 Hospital Systems SANTA MONICA, California — October 8, 2020 — TigerConnect, healthcare’s most widely adopted care team...
Kit Check and Sandoz Collaborate to Launch RFID-tagged Generic Injectables in October 2020 DoseID members, Kit Check and Sandoz, have agreed to launch RFID-tagged injectable medicines Two NDCs of Sandoz RFID-tagged medicines will be available in October 2020, with...
Kit Check Extends Partnership with Premier Inc. in Multi-Year Contract to Further Advance Pharmacy Visibility with Diversion Detection Software and Medication Management WASHINGTON, D.C.–(BUSINESS WIRE)–Kit Check, the leader in automated and intelligent medication...
CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease Novel Approach Aimed at Restoring Brain Functionality September 15, 2020 — San Mateo, Calif.—CuraSen...
Recent Comments